nach oben

Erschienen in:

01.06.2019 | Case report

Rituximab

Infusion related reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a study of 68 patients treated with rituximab for autoimmune diseases between May 2011 and January 2012, one patient [age and sex not stated] was described, who developed an infusion related reaction following administration of rapid infusion of rituximab. The patient, who had autoimmune disease, received IV infusion of rituximab 1000mg followed by a second rituximab infusion after two weeks along with methylprednisolone, paracetamol [acetaminophen] and diphenhydramine administered as premedications. Subsequently, the patient developed infusion related reaction to rituximab in the form of dyspnoea and cough [times to reactions onsets and outcomes not stated]. …

Can M, et al. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: A single-centre experience. Clinical Rheumatology 32: 87-90, No. 1, Jan 2013. Available from: URL: http://doi.org/10.1007/s10067-012-2094-1 - Turkey

Titel: Rituximab
Infusion related reaction: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63854-z

Springer Medizin

Rituximab

Infusion related reaction: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Chlorhexidine

Hyaluronic acid

Antituberculars

Afatinib

Clarithromycin overdose

Docetaxel/gimeracil/oteracil/tegafur/rivoceranib

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Chlorhexidine

Hyaluronic acid

Antituberculars

Afatinib

Clarithromycin overdose

Docetaxel/gimeracil/oteracil/tegafur/rivoceranib